Analysis of U.S. Patent 10,058,504: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,058,504?
U.S. Patent 10,058,504 pertains to a specific class of pharmaceutical compounds and their use. It encompasses:
- Chemical composition: Defines a novel compound or a family of compounds with specific structural motifs.
- Method of synthesis: Details procedures for preparing the compound(s).
- Therapeutic application: Specifies use in treating particular conditions, primarily related to diseases mediated by target biological pathways.
- Formulations: Covers pharmaceutical compositions incorporating the compound.
- Methods of treatment: Claims encompass methods involving administering the compound to treat specified conditions.
The patent does not broadly claim all compounds related to that chemical class but narrows claims to particular structures with specific substituents and configurations.
What are the key claims?
The patent contains 20 independent claims. Highlights include:
-
Compound claims: Cover compounds with a core structure, such as 2,4-diaminoquinazoline derivatives, with particular substituents defined by chemical formulas.
-
Method of synthesis claims: Cover processes for preparing the compounds, including specific reaction sequences, catalysts, or intermediates.
-
Therapeutic method claims: Cover methods for treating diseases such as cancer, involving administering the compounds to patients.
-
Combination claims: Cover pharmaceutical compositions combining the compound with other active agents.
A representative independent claim (paraphrased):
"A compound of formula I, wherein the substituents are defined as X, Y, Z, with specific stereochemistry, for use in the treatment of cancer."
Dependent claims further narrow the scope to specific substituents, stereoisomers, or formulations.
How does the patent landscape look for this technology?
Prior Art
The patent landscape reveals numerous prior art references related to:
- Diaminoquinazoline derivatives: Numerous patents and publications describe structurally similar compounds, especially for kinase inhibition.
- Synthesis methods: Variations of synthetic routes exist, targeting similar chemical scaffolds.
- Therapeutic use: Many patents claim use of quinazoline derivatives as anti-cancer agents, implying a crowded patent space.
- Compound claims: Overlap exists with prior patents claiming broad classes of quinazoline derivatives.
Patentability and Novelty
The patent emphasizes specific structural features or substitution patterns not disclosed in prior art, such as a unique combination of substituents on the core scaffold or a novel synthesis method. Patent examiners likely judged novelty based on these distinctions, supported by experimental data in the application.
Patent families and territorial coverage
- The patent family includes filings in Europe, Japan, China, and other jurisdictions.
- Patent term extends to 2031, assuming maintenance fees are paid.
- Various patent families claim synthetic methods and uses, but the core compound patent remains the key strategic asset.
Competitive landscape
Companies active in kinase inhibitors or cancer therapeutics hold patents with overlapping claims. The landscape includes:
- Large pharmaceutical firms with broad patents on similar compound classes.
- Biotechnology companies targeting niche indications with specific derivatives.
- Challenges from prior art require carve-outs in claims for patent protection.
Other considerations
- Patent life and expiry: Due for expiration in 2031, barring extensions.
- Freedom-to-operate: May require license negotiations if overlapping claims exist.
- Litigation risk: Potential infringement suits from competitors owning related patents.
Key Takeaways
- U.S. Patent 10,058,504 claims specific derivatives within a well-studied class of compounds, with narrowed claims targeting particular substitution patterns.
- The patent’s scope covers compounds, synthesis methods, and therapeutic uses, with enforcement dependent on claim specificity.
- The patent landscape is dense, with prior art on similar quinazoline derivatives, necessitating careful claim drafting for future innovations.
- Strategic value hinges on the novelty of specific structural features and the strength of claims relative to prior art.
- Patent expiration is projected for 2031, but landscape competition remains tight, requiring ongoing freedom-to-operate analysis.
FAQs
1. What is the primary therapeutic application claimed in the patent?
Treatment of cancers, particularly those mediated by kinase signaling pathways.
2. Are the claims broad or narrow?
Claims are relatively narrow, focusing on specific substituents and stereochemistry, reducing overlap with prior art but limiting scope.
3. Is the patent enforceable?
Potentially, if the claims are valid and non-obvious over prior art. Close review of cited references is required for enforcement.
4. Does the patent include claims for formulations?
Yes, it claims pharmaceutical compositions containing the compounds.
5. Can this patent be challenged for validity?
Yes, through opposition or patent invalidation processes based on prior art, novelty, or inventive step challenges.
References
- U.S. Patent and Trademark Office. (2023). Patent 10,058,504. Retrieved from https://patents.google.com/patent/US10058504B2
- European Patent Office. (2022). Patent family documents associated with the family members of US 10,058,504.
- Patent Landscape Reports. (2021). Kinase inhibitor patents in oncology.
[1] U.S. Patent and Trademark Office. (2023). Patent 10,058,504. https://patents.google.com/patent/US10058504B2
